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Abstract
Background: Increasing population rates of cardiac catheterization can lead to the detection of more people with
high risk coronary disease and opportunity for subsequent revascularization. However, such a strategy should only
be undertaken if it is cost-effective.
Methods: Based on data from a cohort of patients undergoing cardiac catheterization, and efficacy data from
clinical trials, we used a Markov model that considered 1) the yield of high-risk cases as the catheterization rate
increases, 2) the long-term survival, quality of life and costs for patients with high risk disease, and 3) the impact of
revascularization on survival, quality of life and costs. The cost per quality-adjusted life year was calculated overall,
and by indication, age, and sex subgroups.
Results: Increasing the catheterization rate was associated with a cost per QALY of CAN$26,470. The cost per QALY
was most attractive in females with Acute Coronary Syndromes (ACS) ($20,320 per QALY gained), and for ACS
patients over 75 years of age ($16,538 per QALY gained). However, there is significant model uncertainty associated
with the efficacy of revascularization.
Conclusion: A strategy of increasing cardiac catheterization rates among eligible patients is associated with a cost
per QALY similar to that of other funded interventions. However, there is significant model uncertainty. A decision
to increase population rates of catheterization requires consideration of the accompanying opportunity costs, and
careful thought towards the most appropriate strategy.
Background
Cardiac catheterization is a diagnostic or interventional
procedure involving insertion of a catheter into a cham-
ber or vessel of the heart. Once inserted contrast dye is
injected and x-rays are taken to identify coronary ste-
noses within the heart [1]. One of the primary purposes
of cardiac catheterization as an intervention is to iden-
tify patients with high-risk coronary artery disease, often
defined as 3-vessel disease or left main disease. This is
because revascularization in suitable patients with high-
risk anatomy using percutaneous coronary intervention
(PCI) or coronary artery bypass grafting (CABG)
improves survival and quality of life [2-5].
Previous work has demonstrated a linear increase in
the number of high-risk coronary artery disease cases
detected when population catheterization rates vary
across their demonstrated range [6]. Although increas-
ing the population catheterization rate may detect more
high risk cases, offering an opportunity to improve
health outcomes through revascularization, any strategy
that increases the use of coronary catheterization will
also expose additional people to the small but well-
known procedural risks of cardiac catheterization, as
well as the more notable risk of subsequent PCI or
CABG if performed. Furthermore, increasing the use of
cardiac catheterization has the potential to incur addi-
tional expenditures for the health care system. Given
the resource constraints of all health care systems,
whether they are publicly or privately funded, there is a
need to formally study the economic implications of
implementing a policy designed to increase catheteriza-
tion rates.
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ment in Coronary Heart (APPROACH) is a prospective
cohort initiative that captures detailed clinical informa-
tion on all patients undergoing cardiac catheterization
within the province of Alberta, Canada (population
approximately 3 million) [7]. APPROACH patients are
followed longitudinally to assess clinical, economic and
quality of life outcomes. This data resource provides a
unique opportunity to conduct an economic evaluation
of a policy designed to increase population cardiac cathe-
terization rates. Using the APPROACH cohort, we esti-
mated clinical event rates, health care costs, and health-
related quality of life (HRQOL) for patients undergoing
catheterization with or without subsequent PCI or
CABG. By combining this information with the incre-
mental yield of high-risk cases that would be detected by
increasing population catheterization rates [6], and the
results of randomized studies documenting the effective-
ness of revascularization relative to medical management,
in patients with high risk disease, we estimated the cost-
effectiveness of increasing the population catheterization
rate compared to maintaining the current rate.
Methods
Study design
We estimated the cost per quality-adjusted life year
(QALY) gained for a strategy of increasing cardiac cathe-
terization rates for patients potentially eligible to undergo
catheterization compared to a contemporary population
catheterization rate from Alberta, Canada (496 per
100,000, the rate seen in 2005), and subsequently for spe-
cific patient subgroups of interest where increasing
catheterization rates might be considered. The subgroups
of a priori interest included indication for catheterization
(acute coronary syndrome (ACS) vs non-ACS), sex, and
age. These are identified subgroups with differential ben-
efit associated with revascularisation [8,9].
Decision analytic model
We used a Markov process to model the cost and clini-
cal outcomes over a patient’s lifetime for patients poten-
tially eligible for catheterization in 1-year time intervals.
A conceptual depiction of the model is presented in Fig-
ure 1. In broad terms, the model captures the possible
events that can ensue when a patient potentially eligible
for catheterization either undergoes cardiac catheteriza-
tion (or not) in both ACS and non-ACS scenarios.
Based on their coronary anatomy (left main disease, 3-
vessel disease, 1-to-2 vessel disease, or normal/near nor-
mal coronaries), and consideration of both patient and
provider preferences, patients are then treated medically
or revascularized, assuming (for the comparator strat-
egy) the existing revascularization rate that was observed
in the APPROACH cohort for patients with left main
disease, 3-vessel disease, 1-to-2 vessel disease, or nor-
mal/near normal coronaries. After undergoing catheteri-
zation and subsequent revascularization as appropriate,
patients then have an on-going risk of death over their
lifetime based on their indication for catheterization
(ACS/non-ACS), age, sex, coronary anatomy, and treat-
ment received. Patients undergoing cardiac catheteriza-
tion who are found to have normal coronary arteries
and have no further treatment are modelled in our Mar-
kov model to experience normal population based rates
of annual mortality.
Among patients who do not undergo catheterization, a
proportion will have undetected high-risk coronary artery
disease - by definition, these patients receive medical
management only. Some of these patients would have
been eligible for revascularization had they undergone a
catheterization, and thus the benefit of an increased
catheterization rate is the additional detection of pre-
viously undetected patients with high-risk coronary anat-
omy who have the potential to benefit from
revascularization, since randomized controlled trials have
demonstrated a survival advantage with revascularization
in this high-risk group [5]. Hence, in our analysis where
we are modelling the effectiveness and cost-effectiveness
of higher catheterization rates, the treatment strategies
differ only by the size of this undetected group - when
population catheterization rates are higher, the number
of patients with high-risk coronary anatomy who are
treated medically becomes smaller because more patients
are detected and revascularized. By implication, the most
important input variables in our analysis relate to the
impact of revascularization in this patient subgroup on
survival, quality of life and health care costs.
Target Population
The target population of interest was all patients poten-
tially eligible to undergo cardiac catheterization. An
assumption inherent to our analysis is that the addi-
tional high risk cases detected among the eligible
patients undergoing catheterization would be similar to
the high risk cases detected using the current rate of
catheterization. To test this assumption, patient demo-
graphics, intervention rates and outcomes were com-
pared across all 9 health regions in Alberta, where age
and sex adjusted catheterization rates varied more than
3-fold. When comparing the high-risk cases across ter-
tiles of utilization, there were no differences in the sur-
vival and revascularization rates between regions,
suggesting that there are few differences between
detected and undetected high-risk cases.
Comparators
The contemporary catheterization rate is based on the
2005 Alberta population catheterization rate taken from
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increased catheterization rate strategy assumes that a
greater proportion of eligible patients within a health
region would receive cardiac catheterization. Given that
the relationship between catheterization rate and high-
risk disease yield has previously been shown to be linear,
the cost per QALY calculated is reported per additional
catheterization done. In-so-far as increasing the cathe-
terization rate results in linearly increasing detection of
high-risk cases [6], the cost per QALY gained by
increasing catheterization rates can be assumed to be
constant.
Model Inputs
1. Patient Cohorts (Table 1)
Ethics approval was obtained from the University of Cal-
gary Conjoint Ethics and Research Board. Three patient
cohorts from APPROACH were used to inform our eco-
nomic evaluation [7]. Patients undergoing catheteriza-
tion between 2004 and 2005 (N = 11,527) were used to
estimate revascularization rates separately for ACS and
non-ACS patients. This cohort was selected to accu-
rately reflect recent practice patterns. A larger patient
cohort (1995-2005, N = 78,881) was selected to estimate
long-term survival, based on ACS-indication, age, sex,
coronary anatomy, and treatment received. A subset of
this cohort with coronary artery disease is followed for-
ward using a mail-out survey, including a quality of life
questionnaire, at 1 year. Only those with complete qual-
ity of life data at 1 year were used to calculate HRQOL
(N = 10,312). Costing data on post-procedural follow-up
care and costs of readmission and subsequent physician
visits, meanwhile, were not available for either of the
recent patient cohorts, but were available for a 1995-
1997 APPROACH cohort (N = 17379) of catheterized
patients [11,12].
2. Catheterization rate and detected disease severity
The 2005 population catheterization rate for Alberta
was 496 per 100,000 adults over 20, with a range of
population catheterization rates of 347 to 542 for
Figure 1 Model structure.
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mum catheterization rate was chosen to reflect, based
on expert opinion, the highest possible catheterization
rate (2,000 per 100,000). The likelihood of undergoing
catheterization is calculated by dividing the number of
catheterizations associated with a given population rate
by number of catheterizations associated with the maxi-
mum population rate.
To calculate the yield of left main, 3-vessel and 1-or
2-vessel disease, a previously published analysis by Gra-
ham et al. was replicated using current data (1995-2006)
[6]. Briefly, using a hierarchical mixed effects linear
model with a random effect for health region, a single
weighted line was plotted to reflect the linear relation-
ship between catheterization rate and disease detection
rate. This resulted in a linear equation where the slope
represents the additional yield of disease case per unit
increase in population catheterization rate. A quadratic
term was included in the model to test for evidence of a
plateau in the yield of high-risk CAD. The quadratic
term was non-significant indicating no evidence of a
plateau in the high-risk CAD cases detected at the high-
est observed catheterization rate. The high-risk model
demonstrated that males have a higher yield of high risk
disease than do females. In males, approximately 1 in 3
catheterizations yields a patient with left main or 3-
vessel disease care whereas in females the ratio is
approximately 1 in 5.
3. Event rates and long-term survival of those catheterized
(Table 1, Figure 2)
Rates of PCI and CABG were calculated by ACS, disease
(i.e. left main disease, 3-vessel disease, 1-to-2 vessel dis-
ease, or normal/near normal coronaries), age and sex
subgroup of patients undergoing cardiac catheterization.
Although the majority of patients with left main and 3-
vessel disease undergo revascularization, some patients
are managed medically (presumably due to patient pre-
ference, severity of comorbid illness, or coronary anat-
omy precluding adequate revascularization). Patients
with left main disease are managed predominantly with
CABG, whereas patients with 3-vessel disease appear to
undergo PCI or CABG equally. For the “standard care
comparator strategy”, we assumed that the same propor-
tion of patients would be eligible to undergo revasculari-
zation (i.e. PCI, CABG) as those who currently receive
catheterization.
Long-term survival data for the larger cardiac cathe-
terization cohort were available for 10 years. Kaplan-
Meier plots were produced by disease and ACS sub-
group for those revascularized and then separately for
those medically managed. Those revascularized with left
main or 3-vessel disease had better long-term survival
Table 1 Clinical outcomes and utility values, age and sex subgroup (N = 11527)*
Males (n = 7885, 68%) Females (n = 3642, 32%)
Under 65
n = 4684
65-75
n = 1992
Over 75
n = 1209
Under 65
n = 1722
65-75
n = 1038
Over 75
n = 882
Risk of death associated with catheterization (%)** 0.01 0.03 0.01 0.01 0.01 0.06
Left main disease (%,n) 5.3 (247) 11.0 (220) 17.0 (205) 2.3 (40) 4.0 (41) 7.5 (66)
Probability of revascularization (%) 84.2 81.8 68.3 92.5 73.2 71.2
Of those revascularized, probability of receiving CABG (%) 92.8 90.6 84.3 83.8 90.0 83.0
3 -vessel disease (%,n) 21.3 (996) 30.8 (614) 36.2 (438) 9.4 (161) 18.1 (188) 26.9 (237)
Probability of revascularization (%) 82.0 73.5 67.1 75.8 68.1 63.3
Of those revascularized, probability of receiving CABG (%) 44.9 52.3 42.5 50.8 39.8 28.7
1- or 2-vessel disease (%,n) 73.5 (3441) 58.1 (1158) 46.8 (566) 88.3 (1521) 77.9 (809) 65.7 (579)
Probability of revascularization (%) 53.6 54.6 53.2 31.6 41.4 46.8
Of those revascularized, probability of receiving CABG (%) 13.5 21.4 28.2 19.8 21.2 21.0
Mean utility scores (EQ-5D)
Left main disease (n) 275 273 116 45 57 35
Revascularized (mean, SD) 0.77 (0.26) 0.80 (0.22) 0.78 (0.25) 0.76 (0.25) 0.75 (0.29) 0.87 (0.14)
Medical management (mean, SD) 0.81 (0.21) 0.77 (0.26) 0.86 (0.15) 0.87 (0.14) 0.81 (0.21) 0.70 (0.28)
3 -vessel disease (n) 1094 822 350 185 209 181
Revascularized (mean, SD) 0.80 (0.22) 0.81 (0.21) 0.82 (0.21) 0.82 (0.17) 0.80 (0.22) 0.80 (0.22)
Medical management (mean, SD) 0.80 (0.21) 0.79 (0.24) 0.81 (0.22) 0.80 (0.22) 0.81 (0.24) 0.84 (0.22)
1- or 2-vessel disease (n) 3056 1070 357 1181 667 339
Revascularized (mean, SD) 0.81 (0.23) 0.82 (0.23) 0.83 (0.24) 0.81 (0.21) 0.84 (0.20) 0.85 (0.20)
Medical management (mean, SD) 0.81 (0.23) 0.81 (0.23) 0.80 (0.22) 0.82 (0.22) 0.80 (0.24) 0.81 (0.21)
* All inputs are calculated from the Alberta Provincial Project for Outcomes Assessment in Coronary Heart disease database; a prospective on-going registry of all
patients undergoing cardiac catheterization.
**calculated based on patients undergoing catheterization for stable angina dying within 3 days
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from many factors including patient selection, rather
than just the treatment received. However, patients with
1- or 2-vessel disease have similar survival regardless of
whether they are revascularized or medically managed,
particularly in the non-ACS subgroup.To account for
increasing age-related mortality, after 10 years, the
hazard ratios for each of the patient subgroups were
multiplied by the age-specific increment in mortality
risk of the Canadian population [13].
Panel B – Non-ACS subgroup 
Figure 2 Observed 10-year survival of patients undergoing cardiac catheterization in Alberta, categorized by ACS, disease and
treatment subgroup (data is from the Alberta Provincial Project for Outcomes Assessment in Coronary Heart disease database; a
prospective on-going registry of all patients undergoing cardiac catheterization).
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HRQOL estimates were determined for the cohort of
APPROACH patients noted above using self-reported
Euroqol (EQ-5D) index scores completed one year after
catheterization [14]. Mean utility scores were calculated
for patients by age, sex, extent of coronary disease and
revascularization status. We assumed that quality of life
scores for those revascularized and those medically
managed persisted for the patient’s lifetime though this
was varied in sensitivity analysis.
For patients with high-risk coronary disease who are
not catheterized (and thus do not receive revasculariza-
tion), evidence from the MASS-2 trial which compared
CABG, PCI and medical management in patients with
multi-vessel coronary disease was used [15]. SF-36
scores, a measure of general HRQL, was measured in
the MASS-2 study; patients who were revascularized
reported higher SF-36 scores at 6-months and 1-year
c o m p a r e dt ot h o s ew h or e c e i ved medical management
alone. The SF-36 scores were converted to a utility
score using a published, validated algorithm [16-18].
The difference between the scores of those revascular-
ized and those medically managed (0.03) was subse-
quently subtracted from patients potentially eligible for
revascularization with undetected left main and 3-vessel
disease who by definition received only medical manage-
ment. There is no evidence to suggest a HRQOL benefit
with revascularization in 1- or 2-vessel disease. Thus,
the mean utility score in this group of patients for those
potentially revascularized (not undergoing catheteriza-
tion) was assumed to be the same as those undergoing
revascularization.
5. Costs (Table 2)
For those undergoing catheterization, data on costs were
obtained from Alberta Health and Wellness (the sole
payer for hospitalization and physician care in Alberta)
for the 1995-1997 APPROACH cohort. The costs asso-
ciated with catheterization, CABG and PCI were noted
to be $2048, $17,958 and $7,927 respectively, including
procedure costs, and associated hospitalization and phy-
sician costs. Subsequent annual costs were obtained for
hospitalization, ambulatory care, home care, physician
claims and medication costs until March 2001. Ambula-
tory care costs were restricted to cardiac care. Costs
were estimated on an annual basis from the date of first
catheterization, and were adjusted to 2006 dollars using
a yearly health sector inflation factor [19]. Given that
costs were observed to be relatively constant between
years 2 and 3, regardless of what cardiac procedure
treatments patients had received, we assumed that yearly
costs remained constant after three years.
There is uncertainty whether revascularization impacts
the long-term costs of patients with coronary disease
compared with medical management. However, the
RITA-2 trial, a trial comparing PCI to medical manage-
ment in patients with angina, reported similar annual
costs of care over a 3-year period between the treatment
strategies [20]. Thus, we assumed no difference in
annual costs of care between those undergoing catheter-
ization and those not.
6. Efficacy of revascularization (Table 3)
In this study, we estimated survival rates based on
APPROACH patients with high-risk coronary anatomy
who have undergone revascularization, but do not have
survival rates for patients with undetected high-risk cor-
onary disease who receive medical management. To esti-
mate the survival of high-risk patients who receive
medical management within our model, we used a
meta-analysis by Yusuf et al that reported the odds ratio
of mortality associated with CABG compared to medical
therapy for stable (non-ACS) patients with high-risk
coronary disease, by disease severity, for two time peri-
ods; 0-5 years and 0-10 years [5]. Using a validated for-
mula, we converted both odds ratios into a relative risks
and imputed the 5-10 year risk [21]. To calculate the
survival of those not catheterized, we applied the inverse
relative risk for both the 0-5 year and 5-10 year relative
risk to the observed long-term survival data of
APPROACH high-risk patients who were revascularized
by disease severity. The relative risk of death, based on
Yusuf et al., of those medically managed as opposed
with revascularization is 2.33 for patients with left main
disease, 1.59 for 3-vessel disease and 1.27 for 1- or 2-
vessel disease for 0-5 years post-revascularization [5].
During the 5-10 year window after revascularization, the
risk of death for those medically managed appears lower
than those who underwent revascularization (RR of
death with medical management compared to revascu-
larization of 0.74 for left main, 1.00 for 3-vessel and
0.80 for 1- or 2-vessel disease)
Recognizing the trials included in Yusuf’s meta-analy-
sis excluded ACS patients, a second baseline analysis
applied the relative risk from the FRISC-II study to the
ACS subgroup [4,22]. The FRISC-II trial randomized
patients to an early catheterization strategy compared to
a conservative, symptom-guided catheterization strategy.
Thus, FRISC-II did not report the efficacy of revasculari-
z a t i o n ,p e rs e ,a sp a t i e n t si nb o t ha r m sc o u l du n d e r g o
intervention. However, it appeared as though the benefit
seen from early catheterization is due to the increased
use of early revascularization. Two separate relative risks
were applied; 0-2 years and 3-5 years based on the 2
publications of FRISC-II [4,22]. Unlike Yusuf’sm e t a -
analysis for CABG in non-ACS patients, the FRISC-II
results are not reported by disease subgroup. Thus, the
same relative risk had to be applied across all coronary
disease subgroups. While not optimal, given that there
are no RCTs reporting on the efficacy of
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Page 7 of 13revascularization compared with medical management
in ACS patients, this analysis serves as our best estimate
of the efficacy of increasing catheterization rates in ACS
patients. The resulting RR from the FRISC-II trial (ACS
patients) is 1.47 for 0-2 years and 0.88 for 3-5 years
post-revascularization [4,22].
Economic Analysis
A healthcare payer perspective was adopted. Costs and
outcomes were discounted using an annual discount
rate of 5 percent [5,23]. SAS, version 9.1, was used for
all data analysis; all economic modelling was done in
Treeage Pro 2009.
Scenario and Sensitivity Analyses
All sensitivity analyses were completed for the ACS and
non-ACS subgroup separately. The impact of various
high-risk case yields was explored. We considered an
ACS and non-ACS specific yield rate. Subsequently, for
males, the yield was varied from 1 case detected in 2 to
a minimum of 1 case per 4 catheterizations (base case: 1
case detected in 3 catheterizations). For females, a maxi-
mum yield of 1 case detected in 2 and a minimum 1
case detected in 7 catheterizations was considered (base
case: 1 case detected in 5 catheterizations).
The base case utility for patients treated medically or
with PCI or CABG was estimated from the EQ-5D uti-
lity scores taken from the APPROACH cohort. Given its
potential lack of sensitivity to changes in HRQOL, in
sensitivity analysis, a disease-specific measure (the Seat-
tle Angina Questionnaire) was also considered. The
Seattle Angina Questionnaire is a measure of quality of
life (not utility), and thus is not ideal for use in the con-
text of an economic evaluation. However, given there
are no cardiac disease-specific utility instruments, we
applied the quality of life scores from the Seattle Angina
Questionnaire (which range from 0 to 1) to understand
how different utility estimates might impact the cost per
QALY. The resulting utility estimates for those revascu-
larized and those medically managed respectively were
0.87 and 0.71 for left main, 0.83 and 0.72 for 3-vessel
disease and 0.80 and 0.78 for 1- and 2-vessel disease.
We also varied the relative risk associated with revascu-
larization by +/- 25%, and considered a scenario where
a constant survival benefit associated with revasculariza-
tion was assumed over a 10 (rather than five) year time
period. Lastly, procedural costs, and yearly costs of care
were increased and decreased to explore the impact of
changes within these variables on the resultant cost per
QALY.
Probabilistic Sensitivity Analysis
To estimate the overall uncertainty in the model, we
completed a Monte Carlo Simulation for the ACS and
Non-ACS models using the Yusuf estimates of efficacy.
Normal distributions were used for relative risks, utility
estimates and the high-risk yield. Gamma distributions
were used for all cost estimates. Incremental cost-effec-
tiveness scatterplots, with 95% confidence ellipses, were
produced to visually assess the uncertainty in the model.
In addition, cost-effectiveness acceptability curves were
plotted to demonstrate the likelihood that an alternative
is cost-effective at a specified willing-to-pay threshold.
Results
Cost-effectiveness of Increasing Catheterization Rates
Table 4 presents the cost-effectiveness of increasing the
population rate of cardiac catheterization. On average,
the incremental cost per additional catheterization done
is $5,270. The incremental effectiveness per additional
catheterization performed is 0.203 QALYs gained, or 74
healthy days. As such, for every additional potentially
eligible patient undergoing cardiac catheterization,
increasing the catheterization rate is associated with a
cost per QALY gained of $26,470.
When an ACS scenario is considered, applying the
Yusuf relative risks [5] (that were derived on stable
angina patients), the cost per QALY is $23,559 (Table 4).
Within the ACS subgroup, females and those over 75
years of age have the lowest cost per QALY at $20,320
and $16,538 respectively. When the FRISC-II relative risk
[4,22] is applied to the ACS subgroup, the cost per
Table 3 Relative risk of death associated with medical management compared to revascularisation
Non-ACS (by disease)
Time Period Left main 3-vessel 2- and 1-vessel Source
0-5 years (95% CI) 2.33 (1.27-4.60) 1.59 (1.21 - 2.14) 1.27 (0.88-1.85) [5]
5-10 years (95% CI) 0.74 (0.46-1.21) 1.00 (0.87 - 1.14) 0.80 (0.70-0.91) [5]
10 + years (95% CI) 1.00 1.00 1.00 Assumed
ACS (unavailable by disease)
0-2 years 1.47 [22]
2-5 years 0.88 [4]
5+ years 1.00 Assumed
*RR > 1.00 indicates revascularisation more beneficial
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Page 8 of 13QALY increases to $31,438, reflecting the smaller benefit
modelled compared to the Yusuf work (Table 4).
Sensitivity and Scenario Analyses
Table 5 summarizes the various sensitivity analyses
completed. As expected, when the yield of high-risk
cases is lower, the cost per QALY is less attractive. The
cost per QALY is also sensitive to variations is the rela-
tive risk of survival associated with revascularization. Of
note, when the Yusuf relative risk from 0-10 years is
decreased by 25% (the RR after year 10 remains 1.0) as
might be plausible if the additional high risk patients
that are identified benefit less from revascularization,
increasing the catheterization rate becomes more costly
and less effective (dominated) than maintaining the cur-
rent catheterization rate. Using the Seattle Angina Ques-
tionnaire to measure HRQOL, an instrument that
results in more pronounced HRQOL differences
between receiving revascularization compared to medi-
cal management, the cost per QALY is more attractive
in all subgroups.
Probabilistic Sensitivity Analysis
Figure 3 presents the incremental cost-effectiveness
scatterplots. There are points in all four quadrants indi-
cating significant uncertainty in the results. This is lar-
gely due to the wide confidence intervals for the relative
risks of death which cross 1.0 indicating both benefit
and harm associated with revascularization. For the ACS
subgroup, a strategy of increasing the catheterization
rate is associated with a cost per QALY of less than
$50,000, a willingness-to-pay threshold commonly pro-
posed as reasonable value for money [24], in 56.3% of
the simulations. However, 34.1% of the simulations
result in a situation where increasing the catheterization
rates is less effectiveness and more expensive than main-
taining the current catheterization rate; a situation
where a policy should not be adopted. The cost-effec-
tiveness acceptability curve show that at a willingness-
to-pay threshold of $50,000, the probability that a strat-
egy of increased catheterization is cost-effective is 57%.
If the willingness-to-pay threshold is increased to
$100,000, the probability increases slightly to 61%. If the
willingness-to-pay threshold is less than approximately
$25,000 maintaining the current catheterization rate is
the most attractive strategy. The results are similar for
the Non-ACS subgroup.
Discussion
In many health care systems, the availability of coronary
catheterization facilities and access to such procedures
is viewed as a key indicator of the “health” of a health
c a r es y s t e m[ 2 5 ] .A sar e s u l t ,t h ed i a l o g u es u r r o u n d i n g
issues of access to invasive cardiac procedures is politi-
cally charged and loudly debated among providers,
health system decision makers, and the general public.
Table 4 Cost per QALY gained with increased population catheterization rate compared to the current catheterization
rate, overall and by subgroup
Strategy Incremental Costs per
catheterization($)
Incremental Effectiveness per
catheterization
(QALY)
Incremental cost-effectiveness
ratio
($ per QALY)
Overall 5,270 0.203 26,470
ACS subgroup - Yusuf RR 5,329 0.226 23,559
Males 6,047 0.245 24,725
Females 3,801 0.187 20,320
Age < 65 4,733 0.192 24,680
Age 65-75 6,939 0.244 28,495
Age > 75 4,976 0.301 16,538
ACS subgroup - FRISC-II RR 5,136 0.163 31,438
Males 5,838 0.176 33,158
Females 3,645 0.136 26,720
Age < 65 4,622 0.147 31,466
Age 65-75 6,645 0.169 39,405
Age > 75 4,664 0.200 23,360
Non-ACS subgroup - Yusuf
RR
5,219 0.163 32,107
Males 5,686 0.193 29,465
Females 4,228 0.100 43,167
Age < 65 4,534 0.143 31,731
Age 65-75 6,307 0.187 33,748
Age > 75 5,976 0.204 29,286
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Page 9 of 13Yet, such debate over the availability of procedures is
not fully informed, because arguments for more or less
procedures often overlook the economics of providing
increased access through the provision of more proce-
dures. It is in this context that we conducted this eco-
nomic evaluation, with the objective of providing
valuable economic data that can inform the planning of
cardiac catheterization and revascularization resources
at a population level.
We found that a strategy of increasing the population
catheterization rate overall in eligible patients is asso-
ciated with a cost per QALY of $26,470, with cost per
QALY estimates ranging from approximately $23,000 to
$32,000 depending on the subgroups of greatest interest.
Our results appear sensitive to the effectiveness of revas-
cularization among the additional high risk patients that
are identified, and further information on this variable
would be ideal. In addition, probabilistic sensitivity ana-
lysis demonstrates significant model uncertainty with
scatter falling within all four quadrants of the ICER
scatterplots. In Canada, $20,000-$100,000 is often cited
as a range which could be considered good value for
money [26]; a range within which the cost-effectiveness
acceptability curve shows probabilities of 40-61% of
increasing the catheterization rates being cost-effective.
Other countries have cited different threshold values
(₤30,000 in the UK and $50,000 in the US [24,27]).
Our economic evaluation contributes new informa-
tion. An economic analysis of the RITA-2 trial, which
included patients eligible for both PCI and medical
management, found that the upfront costs of PCI are
not recouped within 3 years in cost-savings compared to
medical therapy [20]. Economic analysis of the RITA-3
trial, which assessed a strategy of early catheterisation
versus conservative management in ACS patients found
a cost per QALY of ₤12,000 in this high-risk group [28].
A cost-effectiveness study of the FRISC-2 trial in ACS
patients, with a short-term perspective, reported a cost
per death avoided of 1,404,000 Swedish Krona (CAN $
222,439) associated with an early catheterization strategy
compared to medical management [29]. Interpreting a
cost per death avoided is difficult in the context of
other interventions that are expressed as a cost per
QALY over a lifetime horizon. Results from the COUR-
AGE trial, a contemporary trial comparing PCI to medi-
cal therapy revealed a cost per QALY of US $206,229,
likely due to this study’s inclusion of relatively low risk,
stable patients [30]. Lastly, Griffin et al reported a cost
per QALY of ₤19,000 for CABG compared to medical
management after 6 years of follow-up in patients
Table 5 Sensitivity analyses
Parameter Incremental cost-effectiveness ratio ($ per QALY)
ACS
(Yusuf RR)
ACS
(FRISC-II RR)
Non-ACS
Base case $23,559 $31,438 $32,107
ACS specific yield (2.6:1 for males, 3.4:1 for females) $22,187 $30,768
Non-ACS specific yield (2.5:1 for males, 5:1 for females) $29,593
Disease yield for males (cost per QALY for male subgroup)
Decreased to 4:1 catheterizations per high risk case detected $28,335 $34,139 $34,673
Increased to 2:1 catheterizations per high risk case detected $21,973 $32,167 $25,466
Disease yield for females (cost per QALY for female subgroup)
Decreased to 7:1 catheterizations per high risk case detected $22,485 $27,626 $51,189
Increased to 3:1 catheterizations per high risk case detected $17,410 $24,944 $32,390
Relative risk of death associated with medical management compared to revascularisation
Increase by 25% (revascularization more beneficial) $13,300 $18,717 $17,884
Decrease by 25% (revascularization less beneficial) Dominated $196,414 Dominated
Use of Seattle Angina Questionnaire disease specific quality of life measure $20,975 $27,575 $26,264
Procedural Costs
Increase by 50% $30,631 $41,228 $40,540
Decrease by 25% $16,486 $21,648 $23,674
Costs of care
Increase by 50% $21,193 $27,577 $31,294
Decrease by 25% $24,741 $33,368 $32,513
Discount rate
No discounting $12,324 $15,388 $12,672
3% discount rate $19,300 $25,307 $24,276
6% discount rate $25,617 $34,389 $35,971
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Page 10 of 13deemed eligible for both PCI and CABG [31]. Our ana-
lysis, however, differs from these prior studies and also
expands on them. First, we incorporate quality of life
benefits associated with revascularization recognizing
that the benefit associated with revascularization may be
broader than mortality, thus allowing for a cost per
QALY to be calculated. Our analysis also considers a
lifetime horizon over which additional benefit is
accrued. In addition, our study includes older patients
with more severe disease, where more benefit may be
seen.
Although increasing catheterization rates appears
potentially attractive when considering the cost per
QALY estimate in isolation, it is important to judge it
against the cost-effectiveness of other candidate thera-
peutic innovations (e.g., new cancer chemotherapies, or
a population-based vaccination strategy) that may be
under consideration by health system decision-makers
at any given moment in time. Our cost-effectiveness
estimates, while useful, are thus only part of the answer
to such challenging societal and health funding
decisions.
There are some caveats and limitations to our analysis.
The primary benefit of catheterization and subsequent
revascularization in high-risk patients is increased survi-
val. Our analysis used a relative risk of survival for
revascularization in high risk patients from a meta-ana-
l y s i so ft r i a l sd o n en e a r l y2 0y e a r sa g o[ 5 ] .W h i l et h i s
information could be criticized as out of date, these stu-
dies have been the only RCTs that have compared medi-
cal management to revascularization in high-risk disease
patients (left main and 3-vessel) and these studies con-
tinue to guide care of these patients. It could be argued
that medical management has improved greatly since
Figure 3 Incremental cost-effectiveness scatterplots and cost-effectiveness acceptability curves, by ACS/Non-ACS subgroup.
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Page 11 of 13these trials were completed and if the survival of medi-
cally-managed patients is better now, the advantage of
revascularization could be lower, with a resultant less
attractive cost per QALY. However, it could also be
argued that patient who are managed with revasculariza-
tion also receive medical management (i.e. better blood
pressure control and better management of hyperlipide-
mia), so the relative advantage attributable to revascular-
ization may still be applicable. We also applied more
recent evidence from the FRISC-II trial and found gen-
erally similar results to those produced by the Yusuf
relative risks [4,5,22]. As noted, our results are sensitive
to the estimate used from the effectiveness of revascu-
larization among the additional high risk patients that
are identified; accordingly, further information on this
variable should be sought. Our use of these efficacy esti-
mates in our economic modelling underlines the fact
that our collective knowledge of the benefit of revascu-
larization is somewhat outdated for stable angina
patients (as per the Yusuf meta-analysis) and indirect
for ACS patients (from FRISC-II).
The recent COURAGE trial also warrants mention in
the context of considering efficacy estimates for revascu-
larization in our economic evaluation [32]. That trial
compared contemporary optimized medical therapy vs.
PCI in patients with stable angina and varying degrees
of coronary disease. The study revealed no difference
between groups for the composite endpoint of mortality
o rM I ,b u tas l i g h t l yl o w e rr i s ko fm o r t a l i t yi np a t i e n t s
undergoing PCI (relative risk of 0.87). The lack of cor-
onary anatomy-specific relative risk estimates, the
upfront exclusion of patients with high risk clinical pro-
files, and the study’s focus on only stable angina patients
are all factors that prevent us from using the COUR-
AGE trial as an efficacy input to our economic model.
The feasibility of increasing the catheterization rate is
another component of the decision that is not directly
addressed by our analysis. Our analysis assumes that
additional catheterizations would be performed within
established infrastructure and existing manpower (and
as such that additional capital resources are not
required). If the current facilities are operating at full
capacity, then additional facilities would be required to
increase the number of catheterizations. This would
require additional capital investment which would
increase the cost per additional catheterization done
potentially making the cost per QALY less economically
attractive. Our analysis addresses whether increasing
catheterization rates provides reasonable value for
money but does not address the optimal strategy for
increasing catheterization rates. Given that low catheter-
ization rates may have many reasons and considering
the differences among health care systems, local health
regions will have to consider the most appropriate
strategy for their local health care environment. Finally,
our work does not consider the use of non-invasive test-
ing. Its potential proliferation in coming years may
impact the cost-effectiveness of catheterization as
patient selection and risk-stratification change. Future
work could compare the cost-utility of catheterization to
non-invasive imaging in a well-defined patient popula-
tion. These caveats and limitations notwithstanding, our
study adds new information that can inform the popula-
tion-based planning of cardiac catheterization and revas-
cularization services.
Conclusion
Increasing the population catheterization rate is asso-
ciated with a cost per QALY of $26,470. However,
although the basecase estimate generally supports a
strategy of increasing cardiac catheterization rates within
eligible patients, conclusions about the cost-effectiveness
of increasing the catheterization rate are inconclusive
due to significant model uncertainty associated with the
efficacy of revascularization. In addition, funding deci-
sions also require the careful strategic consideration of
other efficacious health care interventions and the
accompanying opportunity costs.
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